Key facts
- This page summarizes Robin Kramer's Form 4 filing for BIOGEN INC. (BIIB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jul 2021, 16:34.
Robin Kramer - 01 Jul 2021 Form 4 Insider Report for BIOGEN INC. (BIIB)
- Reporting relationship
- Chief Accounting Officer
- Issuer ticker
- BIIB
- Reported as of
- 01 Jul 2021
- Net transaction value
- +$61,759
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2021, 16:34:26 UTC
- Prior SEC filing
- 09 Jun 2021
- Next SEC filing
- 07 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Suzanne Murray, Attorney in Fact for Robin C. Kramer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robin Kramer filed Form 4 for BIOGEN INC. (BIIB) on 02 Jul 2021.
Change
- Previous filing in this sequence was filed on 09 Jun 2021.
- Current net transaction value: +$61,759.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIIB
transaction
Common Stock
Options Exercise
- Transaction value
- $87,579
- Shares
- +251
- Change %
- +36%
- Price
- $348.92
- Shares after
- 945
- Date
- 01 Jul 2021
- Ownership
- Direct
BIIB
transaction
Common Stock
Tax liability
- Transaction value
- $25,820
- Shares
- -74
- Change %
- -7.8%
- Price
- $348.92
- Shares after
- 871
- Date
- 01 Jul 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIIB
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -251
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 504
- Date
- 01 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 251
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.
Footnote F2
The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 07/01/2020.